Literature DB >> 1482660

Adjusted dose continuous infusion of factor VIII in patients with haemophilia A.

U Martinowitz1, S Schulman, S Gitel, H Horozowski, M Heim, D Varon.   

Abstract

Surgical interventions in patients suffering from haemophilia A require infusions of large doses of factor VIII (F VIII) concentrates. These are expensive and may pose a burden on the immune system, which is already compromised in many haemophiliacs. F VIII is usually given as bolus injections, although there are reports on fixed dose continuous infusion. We have developed a continuous infusion programme with dosage adjusted according to daily calculation of the clearance of F VIII. Twenty-four haemophiliacs received a total of 205 d of continuous infusion with F VIII (168 d in hospital, 37 d home therapy). Eighteen patients underwent surgeries (11 elective, seven emergency) and six were treated for serious haemorrhages. We observed a significant, progressive decrease of the clearance of F VIII over the first 5 d from 3.2 (2.8-3.5) to 1.7 (1.3-1.9) ml/kg/h (median and interquartile range). The decrease of the clearance together with the fact that a continuous infusion requires less drug than bolus injections to keep the same minimal concentration, contributed to much lower doses of F VIII than reported in the literature or than required by historical controls, matched for the type of operation. Other advantages of our method are improved safety with stable activities of F VIII, lack of hazardous troughs below the haemostatic range, and the convenience, which permits ambulant therapy even when high doses of F VIII are required.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1482660     DOI: 10.1111/j.1365-2141.1992.tb06951.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  Management of hemophilia in developing countries.

Authors:  R Kashyap; V P Choudhry
Journal:  Indian J Pediatr       Date:  2001-02       Impact factor: 1.967

Review 2.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Haemophilia.

Authors:  M R Cahill; B T Colvin
Journal:  Postgrad Med J       Date:  1997-04       Impact factor: 2.401

4.  Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.

Authors:  Alexander H Miners; Caroline A Sabin; Keith H Tolley; Christine A Lee
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 5.  Modern treatment of haemophilia.

Authors:  E Berntorp; V Boulyjenkov; D Brettler; M Chandy; P Jones; C Lee; J Lusher; P Mannucci; I Peak; K Rickard
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

6.  Obstructive Ileus caused by blood clot after emergency total gastrectomy in a patient with hemophilia A: report of a case.

Authors:  M Onda; K Urazumi; R Abe; K Matsuo
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 7.  Orthopedic disorders of the knee in hemophilia: A current concept review.

Authors:  E Carlos Rodriguez-Merchan; Leonard A Valentino
Journal:  World J Orthop       Date:  2016-06-18

8.  Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.

Authors: 
Journal:  CMAJ       Date:  1995-07-15       Impact factor: 8.262

9.  Low-dose continuous infusion of factor VIII in patients with haemophilia A.

Authors:  Tomaž Prelog; Majda Benedik Dolničar; Lidija Kitanovski
Journal:  Blood Transfus       Date:  2015-11-16       Impact factor: 3.443

10.  A system-approach method for the adjustment of time-varying continuous drug infusion in individual patients: a simulation study.

Authors:  Mária Durisová; Ladislav Dedík
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.